Cargando…
S230. LONG-TERM ANTIPSYCHOTIC MEDICATION IN SCHIZOPHRENIA: BENEFITS, RISKS AND FOLLOW-UP: DATA FROM FINNISH COHORT STUDIES AND SYSTEMATIC REVIEW
BACKGROUND: Millions of people use antipsychotic medications. Thousands of clinicians (often non-psychiatrists) prescribe and monitor them every day. Existing research reports mostly favorable risk-benefit ratio during the first years of schizophrenia, but their risk-benefit ratio and maintenance ef...
Autores principales: | Isohanni, Matti, Miettunen, Jouko, Jääskeläinen, Erika, Moilanen, Jani, Hulkko, Anja, Huhtaniska, Sanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888038/ http://dx.doi.org/10.1093/schbul/sby018.1017 |
Ejemplares similares
-
Longitudinal regional brain volume loss in schizophrenia: Relationship to antipsychotic medication and change in social function
por: Guo, Joyce Y., et al.
Publicado: (2015) -
T78. LONG-TERM PROGNOSIS OF SCHIZOPHRENIA - RESULTS FROM THE NORTHERN FINLAND BIRTH COHORT 1966
por: Jääskeläinen, Erika, et al.
Publicado: (2018) -
Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort
por: Husa, Anja P., et al.
Publicado: (2017) -
F128. THE AGE OF ONSET OF SCHIZOPHRENIA SPECTRUM DISORDERS
por: Miettunen, Jouko, et al.
Publicado: (2018) -
Longitudinal Changes in Total Brain Volume in Schizophrenia: Relation to Symptom Severity, Cognition and Antipsychotic Medication
por: Veijola, Juha, et al.
Publicado: (2014)